Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Multiple Myeloma, Diferuloylmethane Derivative, Curcumin, Bioperine
Eligibility Criteria
Inclusion Criteria: Patients with multiple myeloma who have been previously untreated, are asymptomatic and without serious or imminent complications; or have relapsed or failed treatment with conventional therapy. Adequate hematologic, renal, and hepatic functions. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. Exclusion Criteria: Previously untreated patients with high tumor mass; symptomatic or impending fractures. Patients with significant cardiac disease. Patients with comorbid condition which renders patients at high risk of treatment complications. History of significant neurological or psychiatric disorders.
Sites / Locations
- U.T.M.D. Anderson Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Curcumin
Curcumin + Bioperine
Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.